Dermatology

Mark Nestor reveals groundbreaking insights on botulinum toxin's evolving science, enhancing its efficacy and expanding its medical applications in dermatology.

Discover how botulinum toxin injections in the glabella affect brain function, enhancing mood by altering emotional feedback from frowning.

AI and virtual care revolutionize dermatology, enhancing melanoma detection, expanding patient access and improving efficiency in clinical practices.

Ruxolitinib cream shows promising results in repigmenting vitiligo lesions, enhancing skin appearance and quality of life with a strong safety profile.

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, steroid-free solution.

A new study confirms ICD-10 code L80's high accuracy in identifying vitiligo, especially when combined with treatment data, enhancing clinical research.

Opzelura gains FDA approval as the first topical JAK inhibitor for children with atopic dermatitis, offering a steroid-free treatment option.

Povorcitinib shows promising results for hidradenitis suppurativa, offering significant lesion reduction and pain relief in recent phase 3 trials.

A recent study revealed that hidradenitis suppurativa affects 1% of the global population, highlighting significant gender disparities and the need for further research.

Discover groundbreaking research on hard-to-treat skin conditions like hidradenitis suppurativa and vitiligo at the EADV 2025 Congress in Paris.

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved quality of life for patients.

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for improved skin health.

Hidradenitis suppurativa patients face higher depression and anxiety risks, but biologic treatments may reduce these mental health challenges.

Frequent flares in atopic dermatitis predict future disease severity, highlighting the need for improved treatment strategies, as found in a new study published in JAMA Dermatology.

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation. However, newer research has shown that these diseases can overlap in patients and may even share common pathways.

Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic dermatitis (AD), the most common chronic inflammatory skin condition, affecting up to 15% of people worldwide.

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and have limited treatment options.

In a national study of 55 million children and teens across the U.S., there were 1,240 confirmed cases of hidradenitis suppurativa (HS). Nearly all were aged 10 or older.

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer. While most cases are treatable, a small number can become serious and spread, leading to worse outcomes.

As researchers continue to explore more effective solutions, combining platelet-rich plasma (PRP) with fractional laser therapy has gained increasing attention.

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug semaglutide and allodynia, a painful skin sensitivity.

A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.

A study found that while patients with atopic dermatitis often turn to social media for skincare advice, their decisions are most influenced by healthcare professionals, personal experience, and disease severity.

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.